Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis

Abstract

Strontium ranelate reduces the risk of fracture in post-menopausal osteoporotic women with prevalent fractures for whom quality of life is severely impaired. The SOTI study, which used the SF-36® questionnaire and disease-specific QUALIOST® module, demonstrated that treatment with strontium ranelate improved osteoporotic women's quality of life compared with placebo. Introduction: The Spinal Osteoporosis Therapeutic Intervention (SOTI) study demonstrated the effect of orally administered strontium ranelate versus placebo on the incidence of new vertebral fractures and compared impact on quality of life (QoL). Methods: QoL was assessed 6 monthly over 3 years using the QUALIOST® and SF-36® que..